Late-onset Pompe Disease

Rare Diseases
2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

BioMarin Pharmaceutical
2 programs
1
BMN 701Phase 31 trial
Respiratory muscle strength measurements by different techniques.N/A1 trial
Active Trials
NCT02191917Terminated8Est. Jun 2016
NCT01924845Terminated24Est. Sep 2016
Denali Therapeutics
Denali TherapeuticsCA - South SF
1 program
1
DNL952Phase 11 trial
Active Trials
NCT07354724Not Yet RecruitingEst. Aug 2028
Amicus Therapeutics
Amicus TherapeuticsPA - Philadelphia
1 program
STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERTN/A1 trial
Active Trials
NCT03347253TerminatedEst. Nov 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BioMarin PharmaceuticalBMN 701
Denali TherapeuticsDNL952
Amicus TherapeuticsSTRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT
BioMarin PharmaceuticalRespiratory muscle strength measurements by different techniques.

Clinical Trials (4)

Total enrollment: 32 patients across 4 trials

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Start: Apr 2014Est. completion: Sep 201624 patients
Phase 3Terminated

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Start: Mar 2026Est. completion: Aug 2028
Phase 1Not Yet Recruiting
NCT03347253Amicus TherapeuticsSTRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Start: Dec 2017Est. completion: Nov 2018
N/ATerminated
NCT02191917BioMarin PharmaceuticalRespiratory muscle strength measurements by different techniques.

A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)

Start: Oct 2014Est. completion: Jun 20168 patients
N/ATerminated

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space